<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328521</url>
  </required_header>
  <id_info>
    <org_study_id>S2014-099-03</org_study_id>
    <secondary_id>S2014-120-01</secondary_id>
    <nct_id>NCT02328521</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Nicorandil on Neointima</brief_title>
  <official_title>Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhang Ying Qian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to investigate the effect of oral nicorandil on neointima after
      coronary drug-eluting stent implantation in patients with diabetic mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the era of bare metal stent (BMS), the restenosis rate was about 25%. The introduction of
      drug-eluting stent (DES) reduces restenosis rate to 4%-10%. Neointimal hyperplasia and
      restenosis remain to be problems after DES implantation. Besides, DES causes an increase in
      uncovered struts, late stent thrombosis, neoatherosclerosis, and heterogeneous neointima.
      Diabetes mellitus (DM) results in increased risk for atherosclerosis, in-stent restenosis,
      neoatherosclerosis and late-stent thrombosis. Nicorandil, a hybrid of adenosine
      triphosphate-sensitive potassium (K-ATP) channel opener and nitrates, has been shown to
      reduce target vessel revascularization after stent implantation, target lesion
      revascularization after rotational atherectomy, and restenosis in patients undergoing
      percutaneous coronary intervention (PCI). Intracoronary optical coherence tomography(OCT) has
      emerged as a high-resolution imaging method for analysis of neointima that grows over the
      stent. We aim to examine the effect of nicorandil on the neointima after coronary DES
      implantation in patients with unstable angina and DM.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neointimal thickness (in μm)</measure>
    <time_frame>9 month</time_frame>
    <description>Neointimal thickness is defined as the distance between the stent strut and lumen surface.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neointimal area</measure>
    <time_frame>9 month</time_frame>
    <description>Stent and lumen areas will be measured, and neointimal area is calculated as stent area minus lumen area.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of uncovered stent struts</measure>
    <time_frame>9 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent of uncovered stent struts</measure>
    <time_frame>9 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>characteristics of neointima (number of homogenous neointimal,number of layered neointima, number of heterogeneous neointima)</measure>
    <time_frame>9 month</time_frame>
    <description>The characteristics of neointimal hyperplasia will be assessed and classified into three patterns according to the neointimal signal intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of in-stent neoatherosclerosis</measure>
    <time_frame>9 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>angiographic late lumen loss (in mm)</measure>
    <time_frame>9 month</time_frame>
    <description>Late lumen loss is the difference of baseline and follow-up minimal luminal diameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of restenosis (in %)</measure>
    <time_frame>9 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of major adverse cardiovascular events</measure>
    <time_frame>9 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Angina, Unstable</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Nicorandil group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Nicorandil (Chugai Pharmaceutical Co, Japan). The first dose is given 8h before selective percutaneous coronary intervention, 10mg, oral. After the percutaneous coronary intervention, nicorandil is given for 30 days, 5mg each time, 3 times daily oral.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Nicorandil placebo (Sihuan Pharmaceutical Co, China). The first dose is given 8h before selective percutaneous coronary intervention, 2 tablets, oral. After the percutaneous coronary intervention, placebo is given for 30 days, 1 tablet each time, 3 times daily oral.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicorandil</intervention_name>
    <description>Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.</description>
    <arm_group_label>Nicorandil group</arm_group_label>
    <other_name>Sigmart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicorandil placebo</intervention_name>
    <description>Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>no other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  unstable angina with diabetes mellitus and is not given glibenclamide

          -  have clinical indication of percutaneous coronary intervention

          -  de novo severe stenosis in a native coronary artery

          -  lesion suitable for stent and optical coherence tomography examination

          -  reference vessel size between 2.5 and 4.0mm

          -  drug-eluting stent implantation only

        Exclusion Criteria:

          -  acute myocardial infarction within 2 weeks before percutaneous coronary intervention

          -  contraindications to treatment with nicorandil (allergy, glaucoma, digestive ulcer, is
             currently taking phosphodiesterase-5 inhibitor)

          -  bypass restenosis

          -  PCI history

          -  hypotension

          -  intolerance of platelet inhibitors and statins

          -  impaired liver function

          -  renal insufficiency requiring hemodialysis

          -  pregnancy

          -  connective tissue disease

          -  life expectancy ≤ 12 months

          -  left main coronary artery disease

          -  bypass graft lesion and lesions unsuitable for OCT

          -  unwillingness or inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yundai Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Qian Zhang, M.D.</last_name>
    <phone>86-15652505966</phone>
    <email>niniya731@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yundai Chen, M.D.</last_name>
      <phone>86-010-55499309</phone>
      <email>cyundai@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002 Apr 13;359(9314):1269-75. Erratum in: Lancet 2002 Sep 7;360(9335):806.</citation>
    <PMID>11965271</PMID>
  </reference>
  <reference>
    <citation>Horinaka S, Yabe A, Yagi H, Ishimitsu T, Yamazaki T, Suzuki S, Kohro T, Nagai R; JCAD Study Investigators. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J. 2010 Mar;74(3):503-9. Epub 2010 Jan 18.</citation>
    <PMID>20081320</PMID>
  </reference>
  <reference>
    <citation>Machecourt J, Danchin N, Lablanche JM, Fauvel JM, Bonnet JL, Marliere S, Foote A, Quesada JL, Eltchaninoff H, Vanzetto G; EVASTENT Investigators. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol. 2007 Aug 7;50(6):501-8. Epub 2007 Jul 23.</citation>
    <PMID>17678732</PMID>
  </reference>
  <reference>
    <citation>Kawai Y, Hisamatsu K, Matsubara H, Dan K, Akagi S, Miyaji K, Munemasa M, Fujimoto Y, Kusano KF, Ohe T. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon. Eur Heart J. 2009 Apr;30(7):765-72. doi: 10.1093/eurheartj/ehp077. Epub 2009 Mar 10.</citation>
    <PMID>19276198</PMID>
  </reference>
  <reference>
    <citation>Shehata M. Cardioprotective effects of oral nicorandil use in diabetic patients undergoing elective percutaneous coronary intervention. J Interv Cardiol. 2014 Oct;27(5):472-81. doi: 10.1111/joic.12142. Epub 2014 Aug 30.</citation>
    <PMID>25174952</PMID>
  </reference>
  <reference>
    <citation>Nagoshi R, Shinke T, Otake H, Shite J, Matsumoto D, Kawamori H, Nakagawa M, Kozuki A, Hariki H, Inoue T, Ohsue T, Taniguchi Y, Iwasaki M, Nishio R, Hiranuma N, Konishi A, Kinutani H, Miyoshi N, Takaya T, Yamada S, Yasaka Y, Hayashi T, Yokoyama M, Kato H, Kadotani M, Ohnishi Y, Hirata K. Qualitative and quantitative assessment of stent restenosis by optical coherence tomography: comparison between drug-eluting and bare-metal stents. Circ J. 2013;77(3):652-60. Epub 2012 Dec 21.</citation>
    <PMID>23257388</PMID>
  </reference>
  <reference>
    <citation>Tian F, Chen Y, Liu H, Zhang T, Guo J, Jin Q. Assessment of characteristics of neointimal hyperplasia after drug-eluting stent implantation in patients with diabetes mellitus: an optical coherence tomography analysis. Cardiology. 2014;128(1):34-40. doi: 10.1159/000357612. Epub 2014 Feb 7.</citation>
    <PMID>24514877</PMID>
  </reference>
  <reference>
    <citation>Chen J, Zhou S, Jin J, Tian F, Han Y, Wang J, Liu J, Chen Y. Chronic treatment with trimetazidine after discharge reduces the incidence of restenosis in patients who received coronary stent implantation: a 1-year prospective follow-up study. Int J Cardiol. 2014 Jul 1;174(3):634-9. doi: 10.1016/j.ijcard.2014.04.168. Epub 2014 Apr 21.</citation>
    <PMID>24809921</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>January 17, 2015</last_update_submitted>
  <last_update_submitted_qc>January 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Ying Qian</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Neointima</keyword>
  <keyword>Tomography, Optical Coherence</keyword>
  <keyword>drug-eluting stents</keyword>
  <keyword>Nicorandil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Neointima</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicorandil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

